leisure time -WSS

leisure time

author：leisure time 2025-09-28 02:28:48 - browse：1

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Why the world’s most expensive drug might be worth the price

focus

WSS

Washington mulls new rules to avert another Change Healthcare

The SUPPORT Act is critical to fighting the opioid crisis

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Why the world’s most expensive drug might be worth the price

New Medicare drug pricing powers could soon be upended in court

Primary care physicians play key roles in Alzheimer's management

hotspot

leisure time

focus

How one medical school became remarkably diverse

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Affirmative action in medical school literally saved lives

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

In Memoriam: Notable people who died in 2023

Vertex Pharmaceuticals may move headquarters in Boston

Peter Hotez and the public health issue of online harassment

Patient advocates debate FDA's accelerated approval process

Medical records are filled with copy

Roche subsidiary Foundation Medicine opens new headquarters

focus

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Generative AI mines health records to identify patients’ social needs

As JPM 2024 winds down, some health tech firms project optimism

Washington mulls new rules to avert another Change Healthcare

Readout LOUD podcast: mifepristone case, GLP

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

focus

focus

explore

leisure time